Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial

The Lancet Neurology · Elsevier

Аннотация

Publication date: November 2026 Source: The Lancet Neurology, Volume 25, Issue 11 Author(s): Aravindhan Veerapandiyan, Jamie Eskuri, Chamindra G Laverty, Craig M McDonald, Han Phan, Edward C Smith, Carolina Tesi Rocha, Brenda Wong, Marc Morris, Yvonne Tami, Tara Carmack, Philip Kovach, Josiah J Herzog, Steven G Hughes, Yiming Zhu, Elizabeth J Ackermann, Kevin M Flanigan, EXPLORE44 Study Investigators

Читать у издателя →

Похожие статьи